Melanoma genetics and the development of rational therapeutics
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Melanoma is a cancer of the neural crest-derived cells that provide pigmentation to skin and other tissues. Over the past 4 decades, the incidence of melanoma has increased more rapidly than that of any other malignancy in the United States. No current treatments substantially enhance patient survival once metastasis has occurred. This review focuses on recent insights into melanoma genetics and new therapeutic approaches being developed based on these advances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 2×
“BRAFV599E has been shown to act as a transforming oncogene both in NIH3T3 cells (66) and in an immortalized murine melanocyte cell line (105).”
BackgroundA new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“thereby blocks phosphorylation of pRb by these kinases, keeping pRb in its active state inhibiting cell-cycle progression (35).”
BackgroundHigh frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730 · cited 3×
“org Volume 115 Number 4 April 2005 819 early-stage primary melanomas (65, 81), but others have reported a decreasing mutation frequency in association with more advanced disease (67).”
BackgroundZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 1×
“Initial experiments showed that mice carrying a deletion of the Cdkn2a locus have increased predisposition to tumor development (92).”
BackgroundTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Cited by
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
Stecca, B., Mas, C., Clement, V., Zbinden, M., Correa, R., Piguet, V., Beermann, F., & Ruiz i Altaba, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700776104 · Cited by 530
Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene
Kim, M., Gans, J. D., Nogueira, C., Wang, A., Paik, J.-H., Feng, B., Brennan, C., Hahn, W. C., Cordon-Cardo, C., Wagner, S. N., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.008 · Cited by 392
Cannabinoid receptors as novel targets for the treatment of melanoma
Blázquez, C., Carracedo, A., Barrado, L., José Real, P., Luis Fernández‐Luna, J., Velasco, G., Malumbres, M., Guzmán, M., Blázquez, C., Carracedo, A., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6638fje · Cited by 292
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Waldman, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_68 · Cited by 291
“For example, somatic inactivation of PTEN is found in 10–30% of melanomas (Birck et al. 2000; Chudnovsky et al. 2005; Guldberg et al. 1997; Robertson et al. 1998; Tsao et al. 1998; Zhou et al. 2000), and mutational activation of PIK3CA is found in another ~3% (Board et al.”
BackgroundType 2 Diabetes and the Aging Pancreatic Beta Cell
Gunasekaran, U., & Gannon, M. (2011) · Aging · doi:10.18632/aging.100350 · Cited by 183
mTOR Is Activated in the Majority of Malignant Melanomas
Karbowniczek, M., Spittle, C. S., Morrison, T., Wu, H., & Henske, E. P. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701074 · Cited by 168
Shinozaki, M., O'Day, S. J., Kitago, M., Amersi, F., Kuo, C., Kim, J., Wang, H.-J., & Hoon, D. S. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2120 · Cited by 164
Hauser, J. E., Kadekaro, A. L., Kavanagh, R. J., Wakamatsu, K., Terzieva, S., Schwemberger, S., Babcock, G., Rao, M. B., Ito, S., & Abdel‐Malek, Z. A. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00315.x · Cited by 128
Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis
Nogueira, C., Kim, K.-H., Sung, H., Paraiso, K. H. T., Dannenberg, J.-H., Bosenberg, M., Chin, L., & Kim, M. (2010) · Oncogene · doi:10.1038/onc.2010.349 · Cited by 108
“While activation of the RAS-RAF signaling cascade has been recognized as an obligate event in melanocyte transformation, Khavari and colleagues have demonstrated that activation of BRAF – MAPK requires concomitant AKT activation to effect melanoma development (Chudnovsky et al., 2005).”
BackgroundMontero‐Balaguer, M., Lang, M. R., Sachdev, S. W., Knappmeyer, C., Stewart, R. A., De La Guardia, A., Hatzopoulos, A. K., & Knapik, E. W. (2006) · Developmental Dynamics · doi:10.1002/dvdy.20959 · Cited by 95
“Also, pediatric tumors such as neuroblastoma, the most common neonatal tumor (Brodeur, 2003; Maris, 2005), and melanoma, primarily diagnosed in young adults (Chudnovsky et al., 2005; Chin, 2003), have been linked to abnormal activation of NC differentiation programs.”
BackgroundThe T-box transcription factor, TBX3, is a key substrate of AKT3 in melanomagenesis
Peres, J., Mowla, S., & Prince, S. (2015) · Oncotarget · doi:10.18632/oncotarget.2782 · Cited by 40
“Constitutive activation of the PI3K pathway occurs in approximately 70% of sporadic melanomas due to the loss of PTEN and/or amplification of AKT3 [5, 13–14].”
Background
Metadata
- Authors
- Chudnovsky, Y., Khavari, P. A., & Adams, A. E.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-04-01
- Volume
- 115
- Issue
- 4
- Pages
- 813-824
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2004646359
- Cited by
- 204
- References
- 15
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.